Term ends Oct 1, 2030 · High confidence
20-year base term ends Oct 1, 2030
Held by Ellodi Pharmaceuticals, L.P.
Filed Jul 8, 2016 as application 15/205,390 · Granted Dec 26, 2017
Base term, 20 years from filing
Today
2010
2030
Clock starts
Oct 1, 2010
Oct 1, 2010
Term ends
Oct 1, 2030
Oct 1, 2030
Granted
Dec 26, 2017
Dec 26, 2017
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,387,167, to Oct 1, 2030. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 1, 2010, when application 12/896,005, the earliest non-provisional in its chain, was filed (this one was filed Jul 8, 2016) | Oct 1, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,387,167) | resolves to Oct 1, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 1, 2030 | High confidence |
This family
| US 8,771,729 | In force Dec 2030 | Dec 2030 |
| US 9,486,407 | In force Oct 2030 | Oct 2030 |
| US 9,387,167 | In force Oct 2030 | Oct 2030 |
| US 9,849,084 | this patent Oct 2030 | Oct 2030 |
| US 10,632,069 | In force Oct 2030 | Oct 2030 |
| US 11,246,828 | In force Oct 2030 | Oct 2030 |
| US 11,266,598 | In force Oct 2030 | Oct 2030 |
| US 12,290,598 | In force Oct 2030 | Oct 2030 |
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 4, 2017 Reel 43202, frame 964 | Perrett, Stephen; Cohen, Frederic Jay; Venkatesh, Gopi | Eurand, Inc. | Assignment of Assignor's Interest |
| Aug 4, 2017 Reel 43202, frame 977 | Eurand Incorporated | Aptalis Pharmatech Inc. | Change of Name |
| Aug 4, 2017 Reel 43203, frame 1 | Aptalis Pharmatech, Inc. | Adare Pharmaceuticals, Inc. | Change of Name |
| Dec 4, 2018 Reel 47672, frame 450 | Adare Pharmaceuticals, Inc. | Adare Development I, L.P, | Assignment of Assignor's Interest |
| Dec 18, 2018 Reel 47807, frame 967 | Adare Development I, L.p. | Bank of Montreal | Security Interest |
| Jul 16, 2020 Reel 53228, frame 251 | Adare Development I, L.p. | Adare Pharmaceuticals US, L.P. | Change of Name |
| Sep 22, 2020 Reel 53852, frame 697 | Bank Of Montreal, As Collateral Agent | Adare Pharmaceuticals, Inc.; Adare Development I, L.p.; Adare Pharmaceuticals USA, Inc. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Sep 22, 2020 reel/frame not recorded | Bank Of Montreal, As Collateral Agent | Adare Pharmaceuticals, Inc. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Sep 22, 2020 reel/frame not recorded | Bank Of Montreal, As Collateral Agent | Adare Development I, L.p. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Sep 22, 2020 reel/frame not recorded | Bank Of Montreal, As Collateral Agent | Adare Pharmaceuticals USA, Inc. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Oct 5, 2020 Reel 54003, frame 694 | Adare Development I, L.p. | Adare Pharmaceuticals US, L.P. | Corrective Assignment to Correct the Application Number, Patent Issue Date and the Title Previously Recorded at Reel: 053228 Frame: 0251. Assignor(S) Hereby Confirms the Assignment. |
| Apr 19, 2021 Reel 55966, frame 656 | Adare Pharmaceuticals US, L.P. | Ellodi Pharmaceuticals, L.p. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2030
Term ends Oct 1, 2030. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,387,167, ends no earlier than this term, so it caps nothing.
Citations
28
later US patents cite this one
That is top 25% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.